Filing Details
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
8k filedNASDAQ:RARE
Ultragenyx Pharmaceutical Inc. (RARE) Reports Material Event to SEC
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) filed a Form 8-K with the Securities and Exchange Commission on August 11, 2026, disclosing a material event.
At publication ·
What changed
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) · 8k filed
- Form
- 8-K
At a glance
Key takeaways
- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) filed a Form 8-K with the SEC on August 11, 2026, disclosing a material event that shareholders should be aware of.
- The company's stock trades at $26.96 with a market capitalization of $3.5 billion.
- The article does not specify the nature of the material event, which could involve leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance.
Market Context
Ultragenyx Pharmaceutical Inc.'s stock currently trades at $26.96 with a market capitalization of $3.5B. The Healthcare company's stock moved following the disclosure.
8-K filings report material events that shareholders should know about between regular quarterly or annual reports. These can include leadership changes, material agreements, acquisitions, asset sales, or changes to financial guidance. The specific nature of the event determines its significance for Ultragenyx Pharmaceutical Inc.'s stock.
All SEC filings for Ultragenyx Pharmaceutical Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View RARE Stock Page
Frequently Asked Questions
Where can I read RARE's SEC filings?
Browse all filings on our RARE SEC filings page.
What types of SEC filings does Ultragenyx Pharmaceutical Inc. file?
Public companies like Ultragenyx Pharmaceutical Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.